Literature DB >> 31702498

An Investigation of the Anti-Parkinsonism Potential of Co-enzyme Q10 and Co-enzyme Q10 /Levodopa-carbidopa Combination in Mice.

Olakunle J Onaolapo1, Ademola O Odeniyi1, Stephen O Jonathan2, Moyinoluwa O Samuel2, Deborah Amadiegwu2, Ajoke Olawale2, Aisha O Tiamiyu2, Folusho O Ojo2, Hameed A Yahaya2, Oluwadamilare J Ayeni2, Adejoke Y Onaolapo2.   

Abstract

BACKGROUND: Despite decades of research, neurodegenerative disorders like Parkinson's disease remain a leading cause of disability worldwide, due to the insufficient reduction of disease burden by available medications. Recently, the benefits of dietary supplements like co-enzyme Q10 in neurodegenerative diseases have been reported. ; Aim: The protective effects of supplemental co-enzyme Q10 (CQ10) and possible additive benefits of CQ 10/Levodopa-Carbidopa (LD) in Chlorpromazine (CPZ)-induced Parkinsonism-like changes in mice were investigated. ;
Methods: Male mice were assigned to ten groups of 30 mice each. Groups included: Vehicle control (fed Standard Diet (SD), and given intraperitoneal {ip} plus oral saline), LD group (fed SD, and given ip saline plus oral LD), two groups fed CQ10-supplemented diet (at 60 and 120 mg/kg of feed), and given ip plus oral saline, CPZ group (fed SD, and given ip CPZ plus oral saline), CPZ/LD group (fed SD, and given ip CPZ plus oral LD), two groups fed CQ10-supplemented diet (at 60 and 120 mg/kg of feed) and given ip CPZ plus oral saline, and another two groups fed CQ10-supplemented diet (at 60 and 120 mg/kg of feed) and given ip CPZ plus oral LD. The total duration of study was 21 days, and treatments were administered daily. Bodyweight and food intake were measured weekly, while neurobehavioural and biochemical tests were assessed at the end of the experimental period. ;
Results: CQ10-supplementation was protective against CPZ-induced parkinsonism-like changes including, reduction in mortality, the reversal of retardation of open-field behaviours and reduction of catalepsy, increase in dopamine levels and decreased oxidative stress. CQ10 also showed significant improvements in these parameters when co-administered with LD. CQ10 (in groups administered CPZ/CQ10 60) showed greater benefit over LD on anxiety-related behaviours and also had additive benefits on working-memory. ;
Conclusion: Dietary CQ10-supplementation was associated with demonstrable benefits in CPZinduced Parkinsonism-like changes in mice. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Antioxidant; Parkinson's disease; dopamine; electron transfer chain; intraperitoneal; neurobehaviour

Year:  2021        PMID: 31702498     DOI: 10.2174/1874609812666191023153724

Source DB:  PubMed          Journal:  Curr Aging Sci        ISSN: 1874-6098


  5 in total

Review 1.  Coenzyme Q10 and Parkinsonian Syndromes: A Systematic Review.

Authors:  Félix Javier Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  J Pers Med       Date:  2022-06-15

2.  Chronic treatment with coenzyme Q10 mitigates the behavioral dysfunction of global cerebral ischemia/reperfusion injury in rats.

Authors:  Iman Fatemi; Pooya Saeed Askari; Elham Hakimizadeh; Ayat Kaeidi; Sogand Esmaeil Moghaddam; Mohammad Pak-Hashemi; Mohammad Allahtavakoli
Journal:  Iran J Basic Med Sci       Date:  2022-01       Impact factor: 2.532

3.  Preface: Unlocking Aging Science Progress Even During a Time of Lockdown

Authors:  Debomoy K Lahiri; Bryan Maloney; Nigel H Greig
Journal:  Curr Aging Sci       Date:  2021

Review 4.  Coenzyme Q10 Supplementation for the Reduction of Oxidative Stress: Clinical Implications in the Treatment of Chronic Diseases.

Authors:  Francisco Miguel Gutierrez-Mariscal; Antonio Pablo Arenas-de Larriva; Laura Limia-Perez; Juan Luis Romero-Cabrera; Elena Maria Yubero-Serrano; Jose López-Miranda
Journal:  Int J Mol Sci       Date:  2020-10-23       Impact factor: 5.923

5.  Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders.

Authors:  Adejoke Y Onaolapo; Olakunle J Onaolapo
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.